.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC54_RelugolixEstradiolAndNorethister.RelugolixEstradiolAndNorethister .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC54_RelugolixEstradiolAndNorethister.RelugolixEstradiolAndNorethister| name: | RelugolixEstradiolAndNorethisterone |
| ATC code: | H01CC54 | route: | oral |
| n-compartments | 1 |
Relugolix, estradiol, and norethisterone is a fixed-dose combination oral medication used for the management of symptoms associated with uterine fibroids, such as heavy menstrual bleeding, in premenopausal women. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol is a natural estrogen, and norethisterone is a synthetic progestin. This combination is approved for use in several regions and is commonly marketed under the name Myfembree.
Estimate for healthy premenopausal adult females receiving standard oral therapeutic dose as per approved label.